MX2017007272A - Metodos y composiciones para tratar cancer. - Google Patents
Metodos y composiciones para tratar cancer.Info
- Publication number
- MX2017007272A MX2017007272A MX2017007272A MX2017007272A MX2017007272A MX 2017007272 A MX2017007272 A MX 2017007272A MX 2017007272 A MX2017007272 A MX 2017007272A MX 2017007272 A MX2017007272 A MX 2017007272A MX 2017007272 A MX2017007272 A MX 2017007272A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- cells
- il13ra2
- variant
- compositions
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 229960004964 temozolomide Drugs 0.000 abstract 2
- 101000796998 Bacillus subtilis (strain 168) Methylated-DNA-protein-cysteine methyltransferase, inducible Proteins 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 102000003816 Interleukin-13 Human genes 0.000 abstract 1
- 108090000176 Interleukin-13 Proteins 0.000 abstract 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 abstract 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 abstract 1
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000029824 high grade glioma Diseases 0.000 abstract 1
- 201000011614 malignant glioma Diseases 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086346P | 2014-12-02 | 2014-12-02 | |
| PCT/US2015/063267 WO2016089916A1 (en) | 2014-12-02 | 2015-12-01 | Methods and compositons for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017007272A true MX2017007272A (es) | 2018-06-06 |
Family
ID=56078487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007272A MX2017007272A (es) | 2014-12-02 | 2015-12-01 | Metodos y composiciones para tratar cancer. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9650428B2 (enExample) |
| EP (1) | EP3227317A4 (enExample) |
| JP (1) | JP2017537622A (enExample) |
| KR (1) | KR20180041087A (enExample) |
| CN (1) | CN107709353A (enExample) |
| AR (1) | AR102879A1 (enExample) |
| AU (1) | AU2015355084A1 (enExample) |
| BR (1) | BR112017011771A2 (enExample) |
| CA (1) | CA2969714A1 (enExample) |
| EA (1) | EA201791210A1 (enExample) |
| HK (1) | HK1251862A1 (enExample) |
| IL (1) | IL252610A0 (enExample) |
| MX (1) | MX2017007272A (enExample) |
| PH (1) | PH12017501031A1 (enExample) |
| SG (2) | SG10202103475XA (enExample) |
| TW (1) | TW201636425A (enExample) |
| UY (1) | UY36418A (enExample) |
| WO (1) | WO2016089916A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013112871A1 (en) | 2012-01-27 | 2013-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic il-13 polypeptides |
| US9738696B2 (en) | 2012-08-09 | 2017-08-22 | The Board Of Trustees Of The Leland Stanford Junior University | Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities |
| EP3653212B1 (en) | 2012-12-20 | 2023-04-26 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| JP6936934B2 (ja) | 2013-09-24 | 2021-09-22 | メディシナ セラピューティクス インコーポレイテッド | インターロイキン−４受容体結合融合タンパク質及びその使用 |
| WO2016089916A1 (en) | 2014-12-02 | 2016-06-09 | Roger Williams Hospital | Methods and compositons for treating cancer |
| FI3909972T3 (fi) * | 2015-06-19 | 2024-05-03 | Sebastian Kobold | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä |
| EP3575403A1 (en) * | 2015-08-05 | 2019-12-04 | Yoo Young Pharm Co., Ltd. | Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| WO2018112266A1 (en) * | 2016-12-14 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| JP2020517259A (ja) | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| AU2018347796B2 (en) | 2017-10-10 | 2025-07-24 | Medicenna Therapeutics, Inc. | IL-4-fusion formulations for treatment of central nervous system (CNS) tumors |
| KR20200100654A (ko) * | 2017-11-20 | 2020-08-26 | 프로스펙트 차터케어 알더블유엠씨, 엘엘씨 디/비/에이 로저 윌리암스 메디컬 센터 | Car-t 세포 기능성을 개선하기 위한 조성물 및 그의 용도 |
| CN112218885B (zh) | 2017-12-20 | 2024-06-18 | 波赛达治疗公司 | Vcar组合物和使用方法 |
| AU2019209428B2 (en) | 2018-01-22 | 2025-06-26 | Endocyte, Inc. | Methods of use for CAR T cells |
| EP3743445A1 (en) * | 2018-01-26 | 2020-12-02 | City of Hope | Chimeric antigen receptors and methods for reducing off target toxicity |
| CA3090089A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CN110144326A (zh) * | 2018-02-12 | 2019-08-20 | 深圳宾德生物技术有限公司 | 一种靶向性抗肿瘤t细胞及其制备方法和应用 |
| CN110157674A (zh) * | 2018-02-12 | 2019-08-23 | 深圳宾德生物技术有限公司 | 一种靶向性t淋巴细胞及其制备方法和应用 |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| TW202000229A (zh) | 2018-02-23 | 2020-01-01 | 美商安德賽特公司 | Car t細胞療法之順序方法 |
| CN108440674A (zh) * | 2018-04-28 | 2018-08-24 | 杭州荣泽生物科技有限公司 | 一种Trop-2特异性嵌合抗原受体细胞制备及其用途 |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| US12419954B2 (en) * | 2020-01-31 | 2025-09-23 | City Of Hope | Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 positive malignancies |
| EP4100428A4 (en) | 2020-02-04 | 2024-03-06 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | CHIMERIC ANTI-DINITROPHENOL ANTIGEN RECEPTORS |
| JP2023539871A (ja) * | 2020-08-26 | 2023-09-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | グリア芽細胞腫を処置するための方法および組成物 |
| EP4210727A4 (en) * | 2020-09-11 | 2024-12-25 | University of Georgia Research Foundation, Inc. | COMPOSITIONS AND METHODS OF USE THEREOF FOR PREVENTING AND TREATING INFLUENZA INFECTIONS |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| CN114907485B (zh) * | 2021-02-08 | 2024-04-26 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| CN113304267B (zh) * | 2021-06-11 | 2022-03-15 | 河南大学 | 肺癌的治疗靶点及其应用 |
| CN114014941B (zh) * | 2022-01-10 | 2022-04-12 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的嵌合抗原受体及其用途 |
| CN116549667B (zh) * | 2023-05-29 | 2024-02-09 | 四川普锐特药业有限公司 | 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965126A (en) * | 1996-03-25 | 1999-10-12 | The Penn State Research Foundation | use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents |
| JP2004500047A (ja) * | 1999-10-20 | 2004-01-08 | ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | キメラ免疫原性組成物およびこれらをコードする核酸 |
| JP2005518800A (ja) * | 2002-03-01 | 2005-06-30 | ブリストル−マイヤーズ スクイブ カンパニー | 構成的に活性化されたチロシンキナーゼレセプターを発現するトランスジェニック非ヒト哺乳動物 |
| AU2003223497A1 (en) * | 2002-04-05 | 2003-10-27 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
| US7709625B2 (en) * | 2004-06-10 | 2010-05-04 | The Board Of Regents Of The University Of Texas | Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy |
| CA2630334C (en) * | 2005-11-16 | 2013-07-23 | Universidad Nacional Autonoma De Mexico | Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer |
| CN101616685B (zh) * | 2006-03-06 | 2013-07-24 | 阿穆尼克斯运营公司 | 非结构化重组聚合物和其应用 |
| US20080206139A1 (en) * | 2006-11-03 | 2008-08-28 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
| EP4032552B1 (en) * | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| CA2793753C (en) * | 2010-03-26 | 2018-06-05 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
| EP2931893A1 (en) * | 2012-12-13 | 2015-10-21 | Universität Leipzig | T-cell modulation by exon skipping |
| PT3613439T (pt) * | 2013-02-15 | 2021-05-12 | Univ California | Recetor de antigénio quimérico e métodos de utilização do mesmo |
| WO2014164554A1 (en) * | 2013-03-10 | 2014-10-09 | Baylor College Of Medicine | Chemotherapy-resistant immune cells |
| EP3105333B1 (en) * | 2014-02-10 | 2020-04-08 | Emory University | Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer |
| WO2016089916A1 (en) | 2014-12-02 | 2016-06-09 | Roger Williams Hospital | Methods and compositons for treating cancer |
-
2015
- 2015-12-01 WO PCT/US2015/063267 patent/WO2016089916A1/en not_active Ceased
- 2015-12-01 CA CA2969714A patent/CA2969714A1/en not_active Abandoned
- 2015-12-01 BR BR112017011771A patent/BR112017011771A2/pt not_active Application Discontinuation
- 2015-12-01 KR KR1020177018139A patent/KR20180041087A/ko not_active Withdrawn
- 2015-12-01 JP JP2017529284A patent/JP2017537622A/ja active Pending
- 2015-12-01 SG SG10202103475XA patent/SG10202103475XA/en unknown
- 2015-12-01 HK HK18110565.4A patent/HK1251862A1/zh unknown
- 2015-12-01 US US14/956,299 patent/US9650428B2/en not_active Expired - Fee Related
- 2015-12-01 MX MX2017007272A patent/MX2017007272A/es unknown
- 2015-12-01 SG SG11201704519YA patent/SG11201704519YA/en unknown
- 2015-12-01 AU AU2015355084A patent/AU2015355084A1/en not_active Abandoned
- 2015-12-01 EP EP15865800.5A patent/EP3227317A4/en not_active Withdrawn
- 2015-12-01 CN CN201580074883.3A patent/CN107709353A/zh active Pending
- 2015-12-01 EA EA201791210A patent/EA201791210A1/ru unknown
- 2015-12-02 UY UY0001036418A patent/UY36418A/es not_active Application Discontinuation
- 2015-12-02 TW TW104140317A patent/TW201636425A/zh unknown
- 2015-12-02 AR ARP150103939A patent/AR102879A1/es unknown
-
2017
- 2017-05-09 US US15/590,961 patent/US20180072789A1/en not_active Abandoned
- 2017-06-01 IL IL252610A patent/IL252610A0/en unknown
- 2017-06-02 PH PH12017501031A patent/PH12017501031A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107709353A (zh) | 2018-02-16 |
| TW201636425A (zh) | 2016-10-16 |
| US20160151490A1 (en) | 2016-06-02 |
| EP3227317A4 (en) | 2018-04-25 |
| AR102879A1 (es) | 2017-03-29 |
| AU2015355084A1 (en) | 2017-06-29 |
| WO2016089916A1 (en) | 2016-06-09 |
| PH12017501031A1 (en) | 2017-11-27 |
| US9650428B2 (en) | 2017-05-16 |
| BR112017011771A2 (pt) | 2018-07-10 |
| KR20180041087A (ko) | 2018-04-23 |
| SG10202103475XA (en) | 2021-05-28 |
| CA2969714A1 (en) | 2016-06-09 |
| EP3227317A1 (en) | 2017-10-11 |
| UY36418A (es) | 2016-06-30 |
| EA201791210A1 (ru) | 2017-11-30 |
| SG11201704519YA (en) | 2017-07-28 |
| JP2017537622A (ja) | 2017-12-21 |
| IL252610A0 (en) | 2017-07-31 |
| HK1251862A1 (zh) | 2019-04-26 |
| US20180072789A1 (en) | 2018-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501031A1 (en) | Methods and compositions for treating cancer | |
| PH12019500193A1 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| MX2017013298A (es) | Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b. | |
| MX2023007045A (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos. | |
| PH12018502400A1 (en) | Anti-tim-3 antibodies and methods of use thereof | |
| MX2019012223A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
| AU2018291128A1 (en) | Anti-B-cell maturation antigen chimeric antigen receptors with human domains | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| WO2018098365A3 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| GB2557123A (en) | Modified cells and methods of therapy | |
| MX2018006973A (es) | Anticuerpos anti-cd73 humanizados. | |
| GB2564823A (en) | Compositions and methods for T-cell receptors reprogramming using fusion proteins | |
| EP3964527A3 (en) | Combination therapy for cancer | |
| WO2015109124A3 (en) | Immunomodulatory agents | |
| MX2017012939A (es) | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. | |
| MX2018008978A (es) | Receptores de antigenos quimericos que se dirigen a la variante iii del receptor de factor de crecimiento epidermico. | |
| MX2017001013A (es) | Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1. | |
| MY181834A (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| MX2018008558A (es) | Anticuerpos monoclonales anti-cd47 humanizados, de raton, o quimericos. | |
| EA201890294A1 (ru) | Химерный полипептидный комплекс и способы его получения и применения | |
| MY205850A (en) | Proteins binding bcma, nkg2d and cd16 | |
| PH12018500664B1 (en) | Anti-lag3 antibodies and uses thereof | |
| MY189836A (en) | Antibodies against cd73 and uses thereof | |
| NZ732211A (en) | Combination immunotherapy approach for treatment of cancer | |
| BR112019004711A2 (pt) | receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos |